Galapagos NV (GLPG) Gets a Buy Rating from Morgan Stanley

By Ryan Adsit

Morgan Stanley analyst Matthew Harrison maintained a Buy rating on Galapagos NV (GLPGResearch Report) today and set a price target of $193.00. The company’s shares closed last Monday at $175.55, close to its 52-week high of $191.63.

According to TipRanks.com, Harrison is a 4-star analyst with an average return of 6.1% and a 57.4% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, Global Blood Therapeutics, and Fulcrum Therapeutics Inc.

Currently, the analyst consensus on Galapagos NV is a Strong Buy with an average price target of $188.87, a 9.4% upside from current levels. In a report issued on October 25, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $191.63 and a one-year low of $85.00. Currently, Galapagos NV has an average volume of 116K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.